The role of mannose-binding lectin (MBL) in diabetic retinopathy: A scoping review.

Autor: Dias PB; Clinical Hospital, Federal University of Paraná, Curitiba, Brazil; Department of Ophthalmology, Clinical Hospital, Federal University of Paraná, Curitiba, Brazil., Messias-Reason I; Clinical Hospital, Federal University of Paraná, Curitiba, Brazil., Hokazono K; Department of Ophthalmology, Clinical Hospital, Federal University of Paraná, Curitiba, Brazil., Nisihara R; Clinical Hospital, Federal University of Paraná, Curitiba, Brazil; Department of Medicine, Positivo University, Curitiba, Brazil. Electronic address: renatonisihara@up.edu.br.
Jazyk: angličtina
Zdroj: Immunology letters [Immunol Lett] 2024 Jun; Vol. 267, pp. 106863. Date of Electronic Publication: 2024 May 04.
DOI: 10.1016/j.imlet.2024.106863
Abstrakt: Diabetes mellitus (DM) is a chronic systemic disease characterized by a multifactorial nature, which may lead to several macro and microvascular complications. Diabetic retinopathy (DR) is one of the most severe microvascular complications of DM, which can result in permanent blindness. The mechanisms involved in the pathogenesis of DR are multiple and still poorly understood. Factors such as dysregulation of vascular regeneration, oxidative and hyperosmolar stress in addition to inflammatory processes have been associated with the pathogenesis of DR. Furthermore, compelling evidence shows that components of the immune system, including the complement system, play a relevant role in the development of the disease. Studies suggest that high concentrations of mannose-binding lectin (MBL), an essential component of the complement lectin pathway, may contribute to the development of DR in patients with DM. This review provides an update on the possible role of the complement system, specifically the lectin pathway, in the pathogenesis of DR and discusses the potential of MBL as a non-invasive biomarker for both, the presence and severity of DR, in addition to its potential as a therapeutic target for intervention strategies.
Competing Interests: Declaration of competing interest The authors declare no conflicts of interest.
(Copyright © 2024 European Federation of Immunological Societies. Published by Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: